EMA takes positive stance on Moderna COVID-19 vaccine for adolescents

By The Science Advisory Board staff writers

July 26, 2021 -- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has taken a positive position on marketing authorization for Moderna's COVID-19 vaccine for use in adolescents 12 years of age and older.

Following the EMA's nod, the European Commission will now consider authorizing the use of Moderna's vaccine in this population, Moderna said.

The company is now conducting a clinical study regarding use of its vaccine in children ages 6 months to less than 12 years, according to the firm.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.